Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 78, Issue 5, Pages 941-947Publisher
SPRINGER
DOI: 10.1007/s00280-016-3146-z
Keywords
Lung cancer; EGFR-tyrosine kinase inhibitor; Gefitinib; Hepatic dysfunction; Overweight
Categories
Funding
- Center for Innovative Clinical Medicine, Okayama University Hospital, Japan
- Grants-in-Aid for Scientific Research [16K15458] Funding Source: KAKEN
Ask authors/readers for more resources
Being overweight has been reported to induce hepatic dysfunction during cytotoxic chemotherapy. Severe hepatic dysfunction can also be observed during gefitinib monotherapy, leading to interrupted or discontinued treatment. However, whether being overweight is a risk factor during gefitinib therapy is unknown. We retrospectively reviewed 183 Japanese patients with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor-na < ve non-small cell lung cancer (NSCLC) harboring EGFR mutations, who received gefitinib monotherapy between July 2007 and February 2014. We defined being overweight as having a body mass index (BMI) aeyen 25 kg/m(2) and assessed its potential relationship with aeyengrade 2 hepatic dysfunction. The patient demographics were as follows: 114 women; median age 72 years (range 42-95 years); BMI aeyen 25 kg/m(2), n = 32; performance status 0-1, n = 136; stage IIIB/IV, n = 141; and major EGFR mutations, n = 171. Hepatic dysfunction aeyengrade 2 during the gefitinib therapy was observed in 44 (24.0 %) patients, 22 (50.0 %) of whom interrupted or discontinued treatment. The median duration from gefitinib administration to the development of hepatic dysfunction was 56 days (range 6-1,352 days). Overweight patients were more likely to develop hepatic dysfunction aeyengrade 2 compared to non-overweight patients according to a multivariate analysis adjusted for several confounding factors (hazard ratio 2.24; 95 % confidence interval 1.01-4.95; p = 0.046). These results suggest that being overweight may induce hepatic dysfunction during gefitinib monotherapy in Japanese patients with EGFR-mutated NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available